Last reviewed · How we verify

Mifepristone, Oral, 200 Mg

University of Birmingham · FDA-approved active Small molecule Quality 5/100

Mifepristone, Oral, 200 Mg is a Small molecule drug developed by University of Birmingham. It is currently FDA-approved. Also known as: Mifegyne.

Mifepristone, a 200 mg oral medication marketed by the University of Birmingham, holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection offered by its patent. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic nameMifepristone, Oral, 200 Mg
Also known asMifegyne
SponsorUniversity of Birmingham
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Mifepristone, Oral, 200 Mg

What is Mifepristone, Oral, 200 Mg?

Mifepristone, Oral, 200 Mg is a Small molecule drug developed by University of Birmingham.

Who makes Mifepristone, Oral, 200 Mg?

Mifepristone, Oral, 200 Mg is developed and marketed by University of Birmingham (see full University of Birmingham pipeline at /company/university-of-birmingham).

Is Mifepristone, Oral, 200 Mg also known as anything else?

Mifepristone, Oral, 200 Mg is also known as Mifegyne.

What development phase is Mifepristone, Oral, 200 Mg in?

Mifepristone, Oral, 200 Mg is FDA-approved (marketed).

Related